There are currently 1278 clinical trials in Cleveland, Ohio looking for participants to engage in research studies. Trials are conducted at various facilities, including Cleveland Clinic, Cleveland Clinic Foundation, Case Western Reserve University and University Hospitals Cleveland Medical Center. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Evaluation of an Advanced Lower Extremity Neuroprostheses
Recruiting
The purpose of this study is to evaluate a surgically implanted functional electrical stimulation (FES) system to facilitate exercise, standing, stepping and/or balance in people with various degrees of paralysis.
Gender:
ALL
Ages:
Between 21 years and 75 years
Trial Updated:
10/28/2024
Locations: Louis Stokes Cleveland VA Medical Center, Cleveland, Ohio +1 locations
Conditions: Spinal Cord Injuries, Stroke, Paralysis, Tetraplegia, Paraplegia
Imaging Techniques to Monitor Photosensitizer and sO2 Levels During Photodynamic Therapy of Actinic Keratoses
Recruiting
The purpose of the study is to test a new video device for actinic keratoses. The device takes images of your skin lesions during the treatment, to learn whether this device can predict how well the treatment is working.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/28/2024
Locations: Cleveland Clinic, Case Comprehensive Cancer Center, Cleveland, Ohio
Conditions: Actinic Keratoses
Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
Recruiting
This study is researching an experimental drug called REGN3767, also known as fianlimab (R3767), when combined with another medication called REGN2810, also known as cemiplimab (each individually called a "study drug" or called "study drugs" when combined). The study is focused on patients with a type of skin cancer known as melanoma. The aims of the study are to see how effective the combination of fianlimab and cemiplimab are in treating the melanoma skin cancer, in comparison with a medicati... Read More
Gender:
ALL
Ages:
12 years and above
Trial Updated:
10/28/2024
Locations: University Hospitals Seidmand Cancer Center, Cleveland, Ohio +1 locations
Conditions: Melanoma
Preventing Liver Cancer Mortality Through Imaging With Ultrasound vs. MRI
Recruiting
The study is a randomized trial of two different screening methods for early detection of liver cancer in patients with cirrhosis of the liver. The goal of PREMIUM is to compare an abbreviated version of the diagnostic gold standard for HCC (aMRI) +AFP to the standard-of-care screening (US+AFP) in patients at high risk of developing HCC. The investigators hypothesize that HCC will be detected at earlier stages, allowing for more curative treatments and resulting in a reduction in HCC-related mor... Read More
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
10/24/2024
Locations: Louis Stokes VA Medical Center, Cleveland, OH, Cleveland, Ohio
Conditions: Carcinoma, Hepatocellular, Cirrhosis
Phase I Trial to Evaluate VLP Peanut in Healthy and Peanut Allergic Subjects
Recruiting
This phase I clinical trial is designed to evaluate the safety and tolerability of VLP Peanut in healthy subjects and in subjects with peanut allergy (PA). This clinical trial will evaluate the immunotoxicity profile of VLP Peanut in healthy subjects and assess the immunotoxicity profile and the degree of reactogenicity (allergenicity) in subjects with PA. This clinical trial will also explore preliminary proof of efficacy of VLP Peanut in subjects with PA.
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
10/24/2024
Locations: Cleveland Clinic Foundation, Cleveland, Ohio
Conditions: Peanut Allergy
Natural History Study of Individuals With Autism and Germline Heterozygous PTEN Mutations
Recruiting
The purpose of this study is to determine cross-sectional and longitudinal medical, behavioral, and cognitive differences between PTEN ASD and other groups, as well as to identify cognitive, neural systems, and molecular biomarkers specific to PTEN ASD. In addition, this study will be creating and maintaining a biorepository and linked phenotypic database for PTEN ASD.
Gender:
ALL
Ages:
18 months and above
Trial Updated:
10/24/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: PTEN, ASD, Autism, Macrocephaly, PTEN Hamartoma Tumor Syndrome
A Phase 1/2 Study of BA3071 in Patients With Solid Tumors
Recruiting
The objective of this study is to assess safety and efficacy of BA3071 in solid tumors
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: University Hospitals Cleveland Medical Center, Cleveland, Ohio
Conditions: NSCLC, Melanoma
A Study of AdAPT-001 in Subjects With Sarcoma and Refractory Solid Tumors
Recruiting
AdAPT-001 is an oncolytic virus that is injected directly into the tumor or via intraarterial administration. The purpose of this study is to find out if AdAPT-001 is safe and tolerable. The next step is to find out if AdAPT-001 if efficacious with or without a checkpoint inhibitor.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/24/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Solid Tumor, Adult, Cancer, Neoplasms, Sarcoma, Sarcoma,Soft Tissue, Chondrosarcoma
A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination with Venetoclax/Azacitidine, Venetoclax, or 7+3 in Patients with AML
Recruiting
This Phase 1 study will assess the safety, tolerability, and preliminary antileukemic activity of ziftomenib in combination with venetoclax and azacitidine (ven/aza), ven, and 7+3 for two different molecularly-defined arms, NPM1-m and KMT2A-r.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/23/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Acute Myeloid Leukemia, Mixed Lineage Acute Leukemia, Mixed Lineage Leukemia Gene Mutation, Mixed Phenotype Acute Leukemia, Refractory AML, AML With Mutated NPM1, Acute Myeloid Leukemia Recurrent, Acute Myeloid Leukemia, in Relapse, NPM1 Mutation, KMT2Ar, Myeloid Sarcoma
Trial of Therapeutic Hypothermia in Patients With ARDS
Recruiting
Acute Respiratory Distress Syndrome (ARDS) is a serious condition that occurs as a complication of medical and surgical diseases, has a mortality of \~40%, and has no known treatment other than optimization of support. Data from basic research, animal models, and retrospective studies, case series, and small prospective studies suggest that therapeutic hypothermia (TH) similar to that used for cardiac arrest may be lung protective in patients with ARDS; however, shivering is a major complication... Read More
Gender:
ALL
Ages:
Between 18 years and 85 years
Trial Updated:
10/23/2024
Locations: Cleveland Clinc, Cleveland, Ohio
Conditions: Respiratory Distress Syndrome, Adult
Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer
Recruiting
The overarching objective of this project is to develop a pan-gynecologic cancer detection test using gynecologic (unique endometrial, cervical, and ovarian cancer) cancer-specific methylated DNA markers and high-risk human papilloma virus (HR-HPV) detected in vaginal fluid and/or plasma. This proposal defines Phase II MDM-based cancer detection studies in endometrial cancer (EC) and endometrial hyperplasia with atypia (AEH) in tampon-collected vaginal fluid and 2) ovarian cancer (OC) in plasma... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
10/22/2024
Locations: Cleveland Clinic, Cleveland, Ohio
Conditions: Endometrial Cancer, Cervical Cancer, Atypical Endometrial Hyperplasia, Cervical Dysplasia, Adnexal Mass, Ovarian Cancer
Long-Term Safety of Lutetium (177Lu) Vipivotide Tetraxetan in Participants With Prostate Cancer
Recruiting
The purpose of this post-marketing study is to further characterize the long-term outcome of known or potential risks of lutetium (177Lu) vipivotide tetraxetan also known as \[177Lu\]Lu-PSMA-617 or 177Lu-PSMA-617 and hereinafter referred to as AAA617. The study also seeks to further characterize (as possible) any other serious adverse reaction(s) in the long-term in adults with prostate cancer who received at least one dose of AAA617 from interventional, Phase I-IV Novartis sponsored clinical tr... Read More
Gender:
MALE
Ages:
18 years and above
Trial Updated:
10/21/2024
Locations: Cleveland Clinic Foundation, Cleveland, Ohio
Conditions: Prostate Cancer